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Neutrophil Curve Index to Predict Early Infection in
Hematopoietic Stem Cell Transplantation Recipients
Shun-ichi Kimura, Kumi Oshima, Ken Sato, Miki Sato, Kiriko Terasako, Hideki Nakasone,
Misato Kikuchi, Shinya Okuda, Shinichi Kako, Rie Yamazaki, Yukie Tanaka, Aki Tanihara,
Junji Nishida, Yoshinobu KandaWe investigated the impact of neutropenia on the development of early bloodstream and pulmonary
infections in hematopoietic stem cell transplantation (HSCT) recipients, and evaluated the utility of an index
(D-index) that reflects both the intensity and duration of neutropenia. Fifty-eight patients (23 autologous, 35
allogeneic HSCTrecipients) were enrolled in this retrospective study. The D-index was defined as the area
over the neutrophil curve during neutropenia. We also evaluated the utility of the cumulative D-index from
the start of neutropenia until the development of infection (c-D-index), which may enable real-time assess-
ment of the risk for infection. The patients showed 12 and 7 episodes of bloodstream and pulmonary infec-
tion, respectively. The D-index, days of neutropenia (\500/mL) and days of profound neutropenia (\100/mL)
had at least a nearly significant impact on the development of both bloodstream and pulmonary infections.
On the other hand, the c-D-index, cumulative days of neutropenia, and cumulative days of profound neutro-
penia significantly affected pulmonary infection, but not bloodstream infection. The c-D-index had a high
negative predictive value of 97.4% for pulmonary infection with a cutoff of 5500, but the area under the
receiver operating characteristic curve was similar to that of the cumulative days of neutropenia and
profound neutropenia. Our results showed that although the c-D-index may be useful for identifying patients
who are at low risk for early pulmonary infection after HSCT, its performance was similar to that of the
simple duration of neutropenia.
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Pulmonary infectionINTRODUCTION
Infection remains the leading cause of morbidity
and mortality in the early period after hematopoietic
stem cell transplantation (HSCT) [1-6]. Common
sites of infection include the bloodstream and the
lungs [7]. During the neutropenic period before
engraftment, both autologous and allogeneic HSCT
recipients have 2 critical risk factors for infection:Division of Hematology, Saitama Medical Center, Jichi
al University, Saitana, Japan.
isclosure: See Acknowledgments on page 1360.
dence and reprint requests: Yoshinobu Kanda, MD,
on ofHematology, SaitamaMedical Center, JichiMedical
rsity, 1-847 Amanuma, Omiya-ku, Saitama-city, Saitama
503, Japan (e-mail: ycanda-tky@umin.ac.jp).
arch 19, 2010; accepted April 19, 2010
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2010.04.012prolonged severe neutropenia, and breaks in themuco-
cutaneous barrier resulting from preparative regimens
[8,9]. The latter increase the risk of infection caused by
oral, gastrointestinal, and skin flora [10], which results
in bloodstream infections through bacterial transloca-
tion [11]. Although neutropenia is a well-recognized
risk factor for documented infections in the early pe-
riod of HSCT [1], it is still unclear whether it has sim-
ilar or different effects on the development of
bloodstream and pulmonary infections. In addition,
there is no useful index that reflects both the intensity
and duration of neutropenia.
In this study, we retrospectively investigated the
impact of neutropenia on the development of early
bloodstream and pulmonary infections in HSCT re-
cipients. As indexes of the severity of neutropenia, we
used the D-index and c-D-index, which were re-
cently proposed by Portugal et al. [12]. The D-index
was based on a graph that showed the absolute neu-
trophil count during neutropenia and was calculated
as the area over the neutrophil curve (Figure 1).1355
Duration of Neutropenia(days)
1716151413121110987654321
L
u/
 slihp
ort
u
e
N
 f
o
 
.
o
N
500
400
300
200
100
0
D-index
Ae
Ao
Figure 1. Area over the neutrophil curve (D-index) of a hypothetical
neutropenic patient. If the duration of neutropenia is 16 days, the
expected neutrophil area (shaded area, Ae) is 16  500 5 8000. If the
area under the neutrophil curve calculated by the trapezoidal method
(striped area, Ao) is 2062, the D-index 5 8000 2 2062 5 5938.
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neutropenia, and combined both intensity and dura-
tion. However, the neutrophil counts for the whole
duration of neutropenia are required to calculate
the D-index. Therefore, the D-index becomes avail-
able only after the recovery of neutropenia and is not
useful as a predictor of infectious complications. To
resolve this problem, a cumulative D-index (c-D-
index), defined as the cumulative D-index from the
start of neutropenia, was also investigated. Accord-
ing to their study, the D-index and c-D-index had
high negative predictive values for invasive mold in-
fections in acute myelogenous leukemia patients un-
dergoing chemotherapy. This study was performed
to identify the utility of these indexes for predicting
early bloodstream and pulmonary infections in
HSCT recipients.PATIENTS AND METHODS
Patients
The Transplantation Unit of Saitama Medical
Center, JichiMedical University has 3 individual rooms
and 2 quad rooms (11 beds in total) that are equipped
with a laminar air-flow (LAF) system with high-
efficiency particulate air (HEPA) filters. In principle,
allogeneic and autologous HSCTs are performed in
these individual and quad rooms, respectively. We ret-
rospectively reviewed the charts of consecutive patients
who underwent autologous or allogeneic HSCT,
between April 2005 and March 2009. Patients who
had already developed documented infections before
HSCT were excluded. Twenty-three autologous and35 allogeneic HSCT recipients were finally included
in this study.
Transplantation Procedure
The conditioning regimen in autologous HSCT
was mainly a combination of ranimustine, etoposide,
cytarabine, and melphalan (M-BEAM) for lymphoma
(n5 9) and high-dosemelphalan (Mel) formultiplemy-
eloma (n5 13) [13]. One patient with acute promyelo-
cytic leukemia received a combination of busulfan (Bu)
and Mel [14]. In allogeneic HSCT, the combination
of cyclophosphamide (Cy) and either total body irradia-
tion (TBI) (n5 16) or Bu (n5 2) was used as a myeloa-
blative regimen [15].High-dose cytarabinewas added to
Cy and TBI in 2 patients. Fludarabine (Flu)-based re-
duced-intensity regimens, such as Flu combined with
Bu [16] orMel [17], were used in elderly or clinically in-
firm patients (n5 10). Patients with severe aplastic ane-
mia were prepared with Flu, Cy, antithymoglobulin
(ATG) and low-dose TBI at 2 Gy (n 5 2) [18].
Alemutuzumab-containing regimens were used in
HSCT from a 2- or 3-antigen-mismatched donor
(n 5 3) [19]. Regimen-related toxicity was graded
according to Bearman’s criteria [20].
Graft-versus-host disease (GVHD) prophylaxis in
allogeneic HSCT consisted of the continuous infusion
of cyclosporine A with a starting dose of 3 mg/kg/day
and short-term methotrexate (10-15 mg/m2 on day 1,
7-10 mg/m2 on days 3 and 6, and optionally on day 11
inHSCTfromadonorother thananHLA-matched sib-
ling) [21] with the exception of 1 patient who received
a continuous infusion of tacrolimus with a starting
dose of 0.03 mg/kg/day and short-term methotrexate.
Acute GVHD (aGVHD) was graded as previously
described [22].
Prophylaxis against bacterial infections consisted of
levofloxacin in all autologous and most of the allogeneic
HSCTs, except that 7 allogeneic recipients had been
receiving fourth-generation cephalosporine or carbape-
nem for fever of unknown origin at HSCT. Prophylaxis
against fungal infections consisted of fluconazole (n 5
17), itraconazole (n5 31), micafungin (n5 7), or other
antimold agents (n5 3). As prophylaxis against Pneumo-
cystis jiroveci infection, sulfamethoxazole/trimethoprim
or inhalation of pentamidinewas used after engraftment.
As prophylaxis against herpes simplex virus infection,
acyclovir was given from days 27 to 35. In allogeneic
HSCT, this was followed by the long-term low-dose
administration of acyclovir for varicella zoster reactiva-
tion [23]. Preemptive therapy with ganciclovir for
cytomegalovirus infectionwas performedbymonitoring
cytomegalovirus antigenemia [24].
D-Index and c-D-Index Calculation
The D-index was calculated based on a graph
that plotted the absolute neutrophil counts over the
Biol Blood Marrow Transplant 16:1355-1361, 2010 1357Novel Neutropenia Index in HSCTcourse of the episode of neutropenia (Figure 1) [12].
The D-index (Ae – Ao) was calculated as the differ-
ence between the observed area under the curve
(Ao), which was calculated by the trapezoidal
method, and the expected neutrophil area (Ae; 500/
mL  days with neutropenia) if the patient did not
develop neutropenia. A cumulative D-index (c-D-in-
dex) was calculated as the cumulative D-index from
the start of neutropenia until the development of in-
fections in patients with early pulmonary or blood-
stream infections, whereas the c-D-index was equal
to the D-index in patients without these infections.
The cumulative duration of neutropenia or profound
neutropenia was defined as the duration of neutrope-
nia until the development of infections in patients
with early pulmonary or bloodstream infections, re-
spectively, whereas it was equal to the entire duration
of neutropenia or profound neutropenia in patients
without these infections.
Definition of Early Bloodstream and Pulmonary
Infections
Early infection was defined as that which devel-
oped between the start of the conditioning regimens
and 1 week after engraftment. Bloodstream infection
was diagnosed by culturing bacteria from the blood.
To distinguish between true bloodstream infections
and contamination, common skin contaminants such
as diphtheroids, Bacillus species, Propionibacterium spe-
cies, coagulase-negative staphylococci, andmicrococci
had to have been cultured in at least 2 consecutive
blood cultures drawn on separate occasions. Pulmo-
nary infection was defined as new pulmonary infiltrate
observed in a chest X-ray or chest computed tomogra-
phy (CT) regardless of microbiological evidence. Clin-
ically apparent noninfectious pulmonary infiltrates,
including those caused by cardiogenic pulmonary
edema or engraftment syndrome, were excluded.
Statistical Considerations
Weevaluated the impact of theD-index, total dura-
tion of neutropenia (\500/mL), and total duration of
profound neutropenia (\100/mL) as indexes of the
severity of neutropenia over the entire duration of neu-
tropenia, whereas we evaluated the c-D-index, cumula-
tive duration of neutropenia, and cumulative duration
of profound neutropenia as indexes of the cumulative
severity of neutropenia from the start of neutropenia.
We assessed the impact of these indexes along with
other epidemiologic and clinical factors, separately for
bloodstream and pulmonary infections.
Dichotomous variables were compared using
Fisher’s exact test, and continuous variables were com-
pared using the Mann-Whitney U test. A P-value of
\.05 was considered to be significant. To assess the
ability of the D-index, c-D-index, and duration of neu-tropenia to predict infections we performed a receiver
operating characteristic (ROC) curve analysis and
calculated the positive and negative predictive values
in this patient population.RESULTS
Patients
The clinical and epidemiologic characteristics of the
patients are shown in Table 1. Among the 58 patients, 1
autologous and 11 allogeneic HSCT recipients devel-
opedbloodstream infections and7 allogeneicHSCTre-
cipients developed pulmonary infections. The median
number of days between HSCT and the development
of bloodstream and pulmonary infections was 9.5 days
(range: 1-24) and 14.5 days (range: 4-27), respectively.
Eleven of the 12 patients developed bloodstream infec-
tions before engraftment and 1 patient did so within 1
weekafter engraftment.Four of the 7patients developed
pulmonary infections before engraftment and the other
3 patients did so within 1 week after engraftment. The
pathogens that caused bloodstream infections included
coagulase-negative staphylococci (n 5 11), Enterococcus
faecium (n5 1),Pseudomonas species (n5 2),Acinetobacter
(n 5 1), and Candida parapsilosis (n 5 1). Two patients
developed bacteremia by multiple pathogens. Although
the causesof pulmonary infectionswerenotproven in all
7 patients, 1 and 3 cases were classified as probable and
possible invasivemold infection, respectively, according
to the European Organization for Research and Treat-
ment ofCancer/Invasive Fungal InfectionsCooperative
Group and the National Institute of Allergy and Infec-
tious Diseases Mycoses Study Group (EORTC/MSG)
revised criteria for invasive fungal infections [25].
Another case did not fulfill the criteria on chest CT,
but mold infection was suspected because of the eleva-
tion of serum b-D glucan. The other case was also
suspected to have mold infection based on the clinical
course and chestX-ray, but chestCTwas not performed
because of the patient’s poor general condition. The
remaining 1 patient developed a unilateral interstitial
pulmonary infiltrate. In 6 of the 7 cases of pulmonary
infection, antifungal treatment with voriconazole or
liposomal amphotericin B was started.Epidemiologic and Clinical Factors
The incidence of both bloodstream and pulmonary
infections was higher in allogeneic HSCT recipients
than in autologous patients (P5 .013 and .022, respec-
tively). However, age, sex, underlying diseases, condi-
tioning regimens, and antifungal prophylaxis did not
show a statistically significant impact on the develop-
ment of either infection. Furthermore, regimen-
related toxicity of the oral mucosa and gastrointestine,
the duration of central venous catheter insertion, and
Table 1. Clinical and Epidemiological Characteristics of the Study Patients
Total Cases
(n 5 58)
Bloodstream
Infection (n 5 12) P-value*
Pulmonary
Infection (n 5 7) P-value†
Age, years median (range) 50.5 (15-64) 43.5 (15-61) .274 41 (21-54) .312
Sex male / female 29 / 29 7 / 5 .517 4 / 3 .687
Autologous / allogeneic HSCTs 23 / 35 1 / 11 .013 0 / 7 .022
Underlying disease .068 .075
Acute myelogenous leukemia 14 (24.1%) 4 (33.3%) 4 (57.1%)
Acute lymphoblastic leukemia 6 (10.3%) 2 (16.7%) 1 (14.3%)
Lymphoma 17 (29.3%) 0 0
Myelodysplastic syndrome 3 (5.2%) 1 (8.3%) 0
Aplastic anemia 4 (6.9%) 2 (16.7%) 1 (14.3%)
Multiple myeloma 11 (19.0%) 1 (8.3%) 0
Others 3 (5.2%) 2 (16.7%) 1 (14.3%)
Conditioning regimen 0.699 .656
Myeloablative regimen 46 (79.3%) 10 (83.3%) 6 (85.7%)
Reduced-intensity regimen 12 (20.7%) 2 (16.7%) 1 (14.3%)
Prophylactic antifungal agent .190 .096
FLCZ 17 (29.3%) 6 (50.0%) 2 (28.6%)
ITCZ 31 (53.4%) 4 (33.3%) 2 (28.6%)
Other antimold agents 10 (17.2%) 2 (16.7%) 3 (42.9%)
Days of neutropenia (<500/mL) median (range) 11.5 (3-40) 17.5 (5-27) .072 24 (13-29) .003
Days of profound neutropenia
(<100/mL) median (range)
8 (0-35) 15 (3-35) .031 18 (8-29) .008
D-index median (range) 4553.5 (942-17,800) 7102.5 (1653.5-13445.5) .055 9816.5 (4599.5-13973) .007
c-D-index median (range) 3374.75 (1378-10,086) .443 7589 (4599.5-11159) .028
Regimen-related toxicity (Bearman’s grade)
Oral mucosa > Grade II 34 (58.6%) 7 (58.3%) .982 6 (85.7%) .121
Gastrointestine > Grade I 21 (36.2%) 3 (25%) .364 3 (42.9%) .696
Days of central venous catheter insertion,
days median (range)
32.5 (0-85) 39 (17-50) 1.000 32 (24-56) .674
Acute GVHD > Grade II‡ 8 (22.9%) 2 (18.1%) .656 1 (14.3%) .546
GVHD indicates graft-versus-host disease; HSCT, hematopoietic stem cell transplantation.
*Compared to cases without bloodstream infection.
†Compared to cases without pulmonary infection.
‡Analyzed only among allogeneic HSCTrecipients.
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tistically significant risk factors for the development of
either early bloodstream or pulmonary infections.Evaluation of Indexes for the Severity of
Neutropenia: D-Index, c-D-Index, and Duration
of Neutropenia
Among the indexes of the severity of neutropenia
over the whole duration of neutropenia, days of pro-
found neutropenia (\100/mL) significantly affected
the development of bloodstream infections (median
15 versus 7 days, P 5 .031). The D-index and days of
neutropenia (\500/mL) tended to be higher or longer
in patients with bloodstream infections, with borderline
significance (median 7102.5 versus 3963.5 and 17.5
versus 10.5 days, P5 .055 and .072, respectively). As in-
dexes of the cumulative severity of neutropenia from the
start of neutropenia, neither the c-D-index, cumulative
duration of neutropenia, nor cumulative duration of
profound neutropenia significantly affected blood-
stream infections (median 3375 versus 3963.5, 8.5 ver-
sus 10.5 days, and 7 versus 7 days, P 5 .443, .397, and
.900, respectively). On the other hand, both the indexes
of the severity of the whole duration of neutropenia, in-
cluding the D-index, days of neutropenia and days ofprofound neutropenia (median 9816.5 versus 3999.5,
24 versus 11 days, and 18 versus 7 days, P 5 .007,
.003, and .008, respectively), and the indexes for the cu-
mulative severity of neutropenia, including the c-D-in-
dex, cumulative duration of neutropenia, and
cumulative duration of profound neutropenia, signifi-
cantly affected pulmonary infections (median 7589 ver-
sus 3999.5, 20 versus 11 days, and 15 versus 7 days, P5
.028, .020, and .024, respectively).When we focused on
the 6 cases with probable, possible, or suspected pulmo-
nary mold infections, the indexes of the severity of neu-
tropenia over the whole duration of neutropenia
significantly affected the development of invasive
mold infections (median 8702 versus 4059, 23 versus
11 days, 17 versus 7 days, P 5 .027, .020, and .027, re-
spectively), whereas the indexes for the cumulative se-
verity of neutropenia affected it with borderline
significance (median 6678 versus 4059, 18 versus11
days, and 15 versus 7 days, P5 .081, .090, and .077, re-
spectively).
ROC analysis revealed that theD-index, c-D-index,
and duration of neutropenia were equally useful
for predicting early pulmonary infections. The area
under the ROC curves were 0.810, 0.801, and 0.832
for the D-index, days of neutropenia and days of pro-
found neutropenia, respectively (Figure 2A). These
A1 - Specificity
1.00.75.50.250.00
ytivitis
n
eS
1.00
.75
.50
.25
0.00
D-index
N500
N100
B
1 - Specificity
1.00.75.50.250.00
ytivitis
n
eS
1.00
.75
.50
.25
0.00
C-D-index
N500
N100
Figure 2. Receiver operating characteristic curves comparing the
D-index with the days of neutropenia (\500/mL, N500) and profound
neutropenia (\100 /mL, N100) (A), and comparing the cumulative
D-index (c-D-index) with the cumulative durations of neutropenia
(\500/mL, N500) and profound neutropenia (\100/mL, N100) (B) as
predictors of pulmonary infection.
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mulative duration of neutropenia, and cumulative dura-
tion of profound neutropenia, respectively (Figure 2B).
The ROC curve was closest to the left corner of the
plot when the thresholds for the D-index, days of neu-
tropenia, and days of profound neutropenia were
7600, 20, and 15, respectively.With the use of these cut-
off values, the sensitivity and specificity for predicting
pulmonary infections were 71.4% and 84.3%, 71.4%
and 78.4%, and 71.4% and 76.5%, respectively. TheTable 2. Predictive Values of Each Parameter for Early Pulmonary
CO value Sen
D-index 7600
Days of neutropenia (<500/mL) 20
Days of profound neutropenia (<100/mL) 15
c-D-index 5500
Cumulative duration of neutropenia 13
Cumulative duration of profound neutropenia 14
CO indicates cutoff; PPV, positive predictive value; NPV, negative predictive vapositive and negative predictive values were 29.4% and
95.1%, 38.7% and 95.6%, and 31.3% and 95.2%, re-
spectively. Similarly, the ROC curve was closest to the
left corner of the plot when the thresholds for the c-
D-index, cumulative duration of neutropenia, and cu-
mulative duration of profound neutropenia were 5500,
13, and 14, respectively. With the use of these cutoff
values, the sensitivity and specificity for predicting pul-
monary infections were 85.7% and 74.7%, 100% and
60.8%, and 71.4% and 72.5%, respectively. The posi-
tive and negative predictive values were 31.6% and
97.4%, 25.9% and 100.0%, and 35.7% and 94.9%, re-
spectively (Table 2).
We did not perform ROC analyses for blood-
stream infections, because none of the indexes for the
severity of neutropenia, except for the total days
of profound neutropenia (\100/mL), significantly
affected early bloodstream infections.DISCUSSION
Bloodstream and pulmonary infections are the main
types of documented infection [7] and are sometimes
fatal in the early period after HSCT [26,27]. In
this study, 12 and 7 of the 58 patients developed
bloodstream infections and pneumonia within 1 week
after engraftment, and these incidences were similar to
those in previous reports [6,7,26]. With regard to the
causative pathogens, Gram-positive organisms, most of
which were coagulase-negative staphylococci, were
the predominant cause of bloodstream infection. As re-
ported previously, Gram-positive bacteria became the
predominant microorganism that caused bloodstream
infections after the introduction of prophylaxis with
fluoroquinolones [1,2,7]. Among 7 cases of pulmonary
infections, 1 and 3 cases were classified as probable
and possible invasive pulmonary mold infection,
respectively, according to the EORTC/MSG revised
criteria [25]. Invasive fungal infection, especially invasive
aspergillosis, is also a life-threatening infectious compli-
cation in the early period after HSCT [28,29].
Neutropenia is considered to be a critical risk factor
for infectious complications in thepreengraftment phase
of HSCT [8-10]. Engels et al. [1] reported that the log-
arithm10 of the neutrophil count was significantly
associated with the risk of infection in bone marrowInfection
sitivity (%) Specificity (%) PPV (%) NPV (%)
71.4 84.3 29.4 95.1
71.4 78.4 38.7 95.6
71.4 76.5 31.3 95.2
85.7 74.7 31.6 97.4
100 60.8 25.9 100
71.4 72.5 35.7 94.9
lue.
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ing to the study by Bonadio et al. [4], most infectious ep-
isodes in HSCT recipients occurred during the
leukopenic period, especially in patients with a deeper
(white blood cell count\200/mL) and prolonged leuko-
penia. Offidani et al. [5] reported that.5 days of an ab-
solute neutrophil count\100/mL was associated with
a higher risk of early infection in autologous HSCT re-
cipients. Marr et al. [30] considered neutropenia as
a time-dependent covariate, and reported that delayed
neutrophil engraftmentwas associatedwith an increased
risk for early invasive aspergillosis in allogeneic HSCT
recipients. However, there has been no tool to assess
the severity of neutropenia that combined both the in-
tensity and the duration until Portugal et al. [12] devel-
oped the D-index and c-D-index, which are calculated
from the neutrophil count curve.
Our present study showed that the cumulative
severity of neutropenia significantly affected early
pulmonary infections in HSCT recipients. In contrast,
although bloodstream infections tended to occur in
patients with a higher D-index and a longer total dura-
tion of neutropenia, the c-D-index and cumulative
duration of neutropenia had no predictive value for
bloodstream infections. This difference may reflect the
fact that bloodstream infections tended to occur earlier
afterHSCT thanpulmonary infections (median 9.5 ver-
sus 14.5 days). Bloodstream infections often occur soon
afterHSCTasa result of bacterial translocation through
oral and gastrointestinalmucosa damaged by the condi-
tioning regimen [11] or in association with the central
venous catheter [31], and therefore are not strongly
related to the duration of neutropenia. With regard to
pulmonary infections, the significant influence of neu-
tropenia on pulmonary infections might be at least
partly because of pulmonary mold infections, for which
prolonged neutropenia is a strong risk factor [30].
The negative predictive value of the c-D-index for
early pulmonary infections after HSCTwas 97.4% us-
ing a cutoff value of 5500. This means that patients
with a c-D-index less than 5500 have little probability
of developing pulmonary infections and are less likely
to require the empiric or preemptive administration of
intensive antimold treatment, if they have received
treatment in a clean room equipped with a LAF
system. However, it can be difficult to calculate the
c-D-index compared to the simple duration of neutro-
penia. Although Portugal et al. [12] reported that the
D-index and c-D-index were superior to the duration
of neutropenia for predicting invasive mold infections
in acute myelogenous leukemia patients with chemo-
therapy, there seemed to be no great difference accord-
ing to their ROC curves. The current study showed
that the D-index and c-D-index were as effective as
the duration of neutropenia for predicting early
pulmonary infection in HSCT recipients, probably
because neutropenia was more severe and uniform inHSCT recipients than in patients with standard che-
motherapy. In fact, the D-index and c-D-index were
strongly correlated with the total days of neutropenia
and the cumulative duration of neutropenia, respec-
tively, in this study (correlation coefficients 0.974
and 0.968, P\ .001 and\ .001, respectively).
We analyzed both autologous and allogeneic
HSCT recipients together, because neutropenia and
mucocutaneous damage are the strongest risk factors
for infections during the first month after HSCT re-
gardless of the type of HSCT. The difference be-
tween autologous and allogeneic HSCT in terms of
the risk of infectious events becomes apparent after
engraftment, for example, because of the use of ste-
roid for the treatment of GVHD. Therefore, the sig-
nificant difference in the incidence of infections
between allogeneic and autologous HSCT recipients
in this study was because of the difference in the du-
ration of neutropenia, as reported in a previous study
[1]. The duration of neutropenia in autologous
HSCT was significantly shorter than that in alloge-
neic HSCT in this study (median 18.5 versus 6.5
days, P\ .001).
There are some limitations in this study. The first
is the small number of patients evaluated. TheD-index
for bloodstream infection and c-D-index for pulmo-
nary mold infection might have attained significance
if the study had been larger. The second limitation is
that the day of the development of pulmonary infec-
tions was considered as the time when pulmonary infil-
trate was detected by imaging tests in this study. The
true occurrence of pulmonary infections might have
been earlier. Third, the predictive value of c-D-index
might vary depending on the anitfungal prophylaxis.
In this study, patients who received fluconazole and
antimold agents as antifungal prophylaxis were evalu-
ated together. In addition, because the positive predic-
tive value of c-D-index for pulmonary infection was
only 31.5%, it may not be useful as a trigger to start
empiric antifungal therapy.
In conclusion, both bloodstream and pulmonary
infections tended to occur more frequently in patients
with a higher D-index and a longer total duration of
neutropenia early after HSCT. On the other hand,
the c-D-index was helpful for predicting the risk of
pulmonary infections, with a high negative predictive
value, but not for predicting bloodstream infections.
In HSCT recipients, the c-D-index was as useful as
the simple duration of neutropenia and therefore
may add little value to the daily practice of autologous
and allogeneic HSCT.ACKNOWLEDGMENTS
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